Blog | Page 17 of 34

Oncotarget News

Oncotarget Sponsors 2023 Ride for Roswell

June 19, 2023

Oncotarget's publisher, Impact Journals, is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer... read more

Figure 1: Proposed pathway of ACSL4-mediated stimulation of quadruple negative breast cancer cells

Oncotarget

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

June 14, 2023

ACSL4 has been demonstrated to play a pivotal role in both normal physiology as well as in a variety of disease states, including breast and other cancers.”BUFFALO, NY- June... read more

Figure 6: LP-284 is selectively lethal in cells with TC-NER deficiency. non-Hodgkin's lymphoma

Oncotarget

LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency

June 12, 2023

we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity including nanomolar potency in fifteen in vitro NHL cell lines and in vivo preclinical NHL models.”BUFFALO, NY- June 12,... read more

Figure 1: Canonical Src regulation involves the transition from an inactive closed state to an active open form.

Oncotarget

Targeting the Src N-Terminal Regulatory Element in Cancer

June 9, 2023

Src is a recognized oncotarget.”BUFFALO, NY- June 9, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “Targeting the Src N-terminal regulatory... read more

Figure 1: Response to docetaxel in second or third line treatment for non-small cell lung cancer after a treatment with chemo-immunotherapy.

Oncotarget

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

June 7, 2023

large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.”BUFFALO, NY- June 7, 2023 –... read more

Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression

Oncotarget

BORIS Gene Mutation and Expression: Link to Breast Cancer Progression

June 5, 2023

The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.”BUFFALO, NY- June 5, 2023 – A new research paper was published... read more

Figure 1: MALAT1-ASO specifically targets MALAT1-lncRNAs.

Oncotarget

Deconstructing the Role of MALAT1 in MAPK-Signaling in Melanoma

May 30, 2023

In this study, we present novel transcriptional dependencies between MALAT1 and MAPK-pathway-associated genes in melanoma.”BUFFALO, NY- May 30, 2023 – A new research paper was published in Oncotarget's Volume 14... read more

Oncotarget

Behind the Study: Molecular Dialogue Between Tumor Cells and Fibroblasts

May 25, 2023

Dr. Gopal C. Kundu from KIIT Deemed to be University in Odisha, India, describes a recent editorial he co-authored that was published by Oncotarget in Volume 14, entitled, “The molecular... read more

Oncotarget

HER3: Survival Pathway and Therapeutic Target in Metastatic Colorectal and Pancreatic Cancer

May 24, 2023

we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC [...].”BUFFALO, NY- May 24, 2023 – A new... read more

Figure 7: Schematic demonstrating the role of GPR141 in mediating breast cancer development and progression.

Oncotarget

GPR141 Regulates Breast Cancer Progression via Oncogenic Mediators and The p-mTOR/p53 Axis

May 22, 2023

This research uncovers GPR141 as a stimulator of breast tumorigenesis and metastasis, making it a candidate target for breast cancer therapeutics.”BUFFALO, NY- May 22, 2023 – A new research paper... read more